Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Scleroderma Therapeutics Market: By Drug Class: Phosphodiesterase 5 Inhibitors - PHA , Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others; By Indication; Regional Analysis; Historical Market and Forecast (2016-2026); Competitive Landscape; Industry Events and Developments
Global Scleroderma Therapeutics Market Outlook
The global scleroderma therapeutics market attained a value of USD 1.7 billion in 2020. The scleroderma therapeutics market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 6.2% to reach USD 2.4 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Properties and Applications
Scleroderma refers to an autoimmune condition that affects the skin, vessels of the blood, muscles, and internal organs. Usually, the disease is caused by an abnormal immune response. Immunosuppressive medicines and, in some cases, glucocorticoids are included to treat this condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The drug class available in the industry can be divided into:
- Immunosuppressors
- Phosphodiesterase 5 Inhibitors - PHA
- Endothelin Receptor Antagonists
- Prostacyclin Analogues
- Calcium Channel Blockers
- Analgesics
- Others
Based on indication, the scleroderma therapeutics market can be divided into:
- Systemic
- Localized
The EMR report looks into the regional markets of scleroderma therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The demand in the industry is mainly being driven by the use of off-label medications approved. The lack of curative drugs and a higher prevalence of off-label drug use are the underlying factors that drive interest in markets for rare diseases. The advancement of targeted biologics, as well as small molecular combination therapies, are expected to be supported in the industry. The market is also projected to be supported by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment. The rising disposable incomes, allowing greater expenditure, and the existence of a well-defined regulatory framework that promotes successful therapy production in developed regions are driving the growth of the industry.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global scleroderma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffman La Roche Ltd.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company [NYSE: BMY]
- arGentis Pharmaceuticals, Llc
- Prometic Life Sciences Inc.
- Akashi Therapeutics
- Kadmon Holdings, Inc.
- Emerald Health Pharmaceuticals.
- Others
The EMR report gives an in-depth insight into the scleroderma therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Indication, Region |
| Breakup by Drug Class | Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others |
| Breakup by Indication | Systemic, Localized |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | F. Hoffman La Roche Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company [BMY (NYSE)], arGentis Pharmaceuticals, Llc, Prometic Life Sciences Inc. [LMNL (TSE)], Akashi Therapeutics, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key findings of the Study
2 Research Methodology
2.1 Data Extraction
2.2 Data Corroboration
2.3 Market Structure
2.4 Inference Data
3 Executive Summary
3.1 Market Overview
3.2 Market Analysis
4 Global Scleroderma Therapeutics Market Analysis
4.1 Global Scleroderma Therapeutics Historical Market (2016-2020) & Forecast (2021-2026)
4.2 Global Scleroderma Therapeutics Market Breakup by Drug Class
4.2.1 Immunosuppressors
4.2.2 Phosphodiesterase 5 Inhibitors - PHA
4.2.3 Endothelin Receptor Antagonists
4.2.4 Prostacyclin Analogues
4.2.5 Calcium Channel Blockers
4.2.6 Analgesics
4.2.7 Others
4.3 Global Scleroderma Therapeutics Market Breakup by Drug Class: Historical Market (2016-2020) & Forecast (2021-2026)
4.3.1 Immunosuppressors
4.3.2 Phosphodiesterase 5 Inhibitors - PHA
4.3.3 Endothelin Receptor Antagonists
4.3.4 Prostacyclin Analogues
4.3.5 Calcium Channel Blockers
4.3.6 Analgesics
4.3.7 Others
4.4 Global Scleroderma Therapeutics Market Breakup by Indication
4.4.1 Systemic
4.4.2 Localized
4.5 Global Scleroderma Therapeutics Market Breakup by Indication: Historical Market (2016-2020) & Forecast (2021-2026)
4.5.1 Systemic
4.5.2 Localized
4.6 Global Scleroderma Therapeutics Market Breakup by Region
4.6.1 North America
4.6.1.1 United States of America
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 United Kingdom
4.6.2.3 France
4.6.2.4 Italy
4.6.2.5 Others
4.6.3 Asia Pacific
4.6.3.1 China
4.6.3.2 Japan
4.6.3.3 India
4.6.3.4 ASEAN
4.6.3.5 Others
4.6.4 Latin America
4.6.4.1 Brazil
4.6.4.2 Argentina
4.6.4.3 Mexico
4.6.4.4 Others
4.6.5 Middle East & Africa
4.6.5.1 Saudi Arabia
4.6.5.2 United Arab Emirates
4.6.5.3 Nigeria
4.6.5.4 South Africa
4.6.5.5 Others
4.7 Global Scleroderma Therapeutics Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
4.7.1 North America
4.7.1.1 United States of America
4.7.1.2 Canada
4.7.2 Europe
4.7.2.1 Germany
4.7.2.2 United Kingdom
4.7.2.3 France
4.7.2.4 Italy
4.7.2.5 Others
4.7.3 Asia Pacific
4.7.3.1 China
4.7.3.2 Japan
4.7.3.3 India
4.7.3.4 ASEAN
4.7.3.5 Others
4.7.4 Latin America
4.7.4.1 Brazil
4.7.4.2 Argentina
4.7.4.3 Mexico
4.7.4.4 Others
4.7.5 Middle East & Africa
4.7.5.1 Saudi Arabia
4.7.5.2 United Arab Emirates
4.7.5.3 Nigeria
4.7.5.4 South Africa
4.7.5.5 Others
5 SWOT Analysis
5.1 Overview
5.2 Strengths
5.3 Weaknesses
5.4 Opportunities
5.5 Threats
6 Porter’s Five Forces Analysis
6.1 Overview
6.2 Buyer’s Power
6.3 Supplier’s Power
6.4 New Entrants
6.5 Degree of Rivalry
6.6 Substitutes
7 Value Chain Analysis
8 EMR’s Key Indicators for Demand
9 EMR’s Key Indicators for Price
10 Competitive Landscape & Supplier Analysis
10.1 F. Hoffman La Roche Ltd.
10.1.1 Company Overview
10.1.2 Financial Analysis
10.2 Boehringer Ingelheim International GmbH
10.2.1 Company Overview
10.2.2 Financial Analysis
10.3 Bristol-Myers Squibb Company [BMY (NYSE)]
10.3.1 Company Overview
10.3.2 Financial Analysis
10.4 arGentis Pharmaceuticals, Llc
10.4.1 Company Overview
10.4.2 Financial Analysis
10.5 Prometic Life Sciences Inc. [LMNL (TSE)]
10.5.1 Company Overview
10.5.2 Financial Analysis
10.6 Akashi Therapeutics
10.6.1 Company Overview
10.6.2 Financial Analysis
10.7 Kadmon Holdings, Inc.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.8 Emerald Health Pharmaceuticals.
10.8.1 Company Overview
10.8.2 Financial Analysis
10.9 Others
11 Industry Events and Developments
Key Questions Answered in the Report
In 2020, the global scleroderma therapeutics market attained a value of nearly USD 1.7 billion.
The market is projected to grow at a CAGR of 6.2% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2021-2026 to reach USD 2.4 billion by 2026.
The major industry drivers include rising population, advancement of targeted biologics, and small molecular combination therapies and the use of off-label medications approved.
The key industry trends driving growth include the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others.
The leading indication types of the industry are systemic and localized.
The major players in the industry are F. Hoffman La Roche Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, arGentis Pharmaceuticals, Llc, Prometic Life Sciences Inc., Akashi Therapeutics, Kadmon Holdings, Inc., and Emerald Health Pharmaceuticals, among others.
Analyst Review
The global scleroderma therapeutics market attained a value of USD 1.7 billion in 2020, driven by the advancement of targeted biologics, as well as small molecular combination therapies and the use of off-label medications approved. Aided by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 6.2%. The market is projected to reach USD 2.4 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others. The leading indication types of the industry are systemic and localized. The major regional markets for scleroderma therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffman La Roche Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, arGentis Pharmaceuticals, Llc, Prometic Life Sciences Inc., Akashi Therapeutics, Kadmon Holdings, Inc., and Emerald Health Pharmaceuticals, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global therapeutic beds market attained a value of USD 3.37 billion in 2020. The market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 5.38% to reach USD 4.61 billion...
The global allergy treatment market attained a value of 17.9 billion in 2020, driven by the growing popularity of immunotherapy. Aided by the growing R&D activities towards the development of anti-all...
The global cancer immunotherapy market stood at a value of around USD 86,607 million in 2020. The market is further expected to grow at a CAGR of 9.7% in the forecast period of 2021-2026 to attain a v...
The global sickle cell disease treatment market stood at a value of around USD 3.4 billion in 2020. The market is further expected to grow at a CAGR of 16.9% in the forecast period of 2021-2026 to att...
The global dry eye disease treatment market attained a value of nearly USD 5 billion in 2020, driven by the rising prevalence of eye complications among the growing geriatric population. Aided by the ...
NEWSLETTER